4DMedical (ASX:4DX): What Does the SimonMed Lung-Imaging Launch Mean for US Access?

Aditi Sarkar

12 November 2026 04:39 PM AEDT

4DMedical (ASX:4DX): What Does the SimonMed Lung-Imaging Launch Mean for US Access?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

4DMedical (ASX:4DX) announced a nationwide SimonMed outpatient imaging launch in November.
Both CT:VQ and LDAf analyse non-contrast chest CT images.
CT:VQ maps regional ventilation and perfusion within the lungs.
The company publishes FY2026 reporting and tracks US commercial adoption.

4DMedical Limited (ASX:4DX) develops software that derives quantitative information about lung function from medical imaging, with products offered to healthcare providers in Australia and the United States. On 12 November 2026, 4DX shares were priced at AUD 2.28, down 3.80% for the session. Its November announcement concerned nationwide outpatient access to two FDA-cleared software products through imaging group SimonMed, adding a new route for physicians to request analyses when assessing patients with respiratory symptoms.

Lung-Imaging Software and Clinical Applications

4DMedical (ASX:4DX) specialises in software analysis rather than Manufacturing conventional CT scanners. Its CT:VQ technology produces regional ventilation and perfusion maps using existing non-contrast chest CT imaging. The company describes ventilation as the distribution of air and perfusion as the distribution of blood flow. LDAf quantifies low-density lung tissue and air trapping, information relevant to evaluating obstructive lung disease. These assessments are intended to complement clinical evaluation and other tests, rather than serve as a standalone diagnosis. Providers can request the analyses individually or together, depending on the clinical question.

SimonMed Launch Extends Outpatient Availability

On 2 November 2026, SimonMed announced that physicians could order CT:VQ and LDAf analyses at its locations across the United States. 4DMedical (ASX:4DX) described SimonMed as its first nationwide US outpatient imaging-group partner. Both products analyse non-contrast chest CT examinations and use specialised software to produce additional information. CT:VQ does not require injected contrast or radioactive tracers for its described functional assessment. The launch increases the settings in which the software can be ordered, but the announcement did not disclose resulting revenue, completed scan numbers or the financial terms of the commercial relationship.

How the Technology Fits Existing Workflows

A central feature of the arrangement is that referring physicians can use established outpatient imaging locations. Patients with persistent shortness of breath, chronic cough, abnormal pulmonary function tests, or known or suspected pulmonary conditions are among the groups identified by 4DMedical (ASX:4DX) as potential candidates for further evaluation. Access remains subject to a physician order, while insurance coverage and patient charges vary by plan. The published launch concerns availability and clinical workflow; it is not a statement about universal reimbursement or evidence that every referred patient will receive both analyses.

Financial Reporting and Commercial Context

4DMedical (ASX:4DX) lists its FY2026 full-year results and Annual Report as released on 30 September 2026, following its July quarterly activity report. These reports provide the appropriate record for assessing sales, spending and liquidity. The November SimonMed announcement does not Supply a new consolidated Earnings result or a financial forecast, so the clinical launch should not be converted into assumed revenue. Commercial uptake can depend on referring-clinician awareness, the rate at which imaging sites implement ordering processes, payer coverage and the extent to which resulting clinical information is used in care pathways.

Execution Risks and Points to Monitor

A broader distribution channel does not itself establish utilisation. 4DMedical (ASX:4DX) must support physicians, imaging groups and clinical teams as the analyses are introduced to outpatient care. Different reimbursement arrangements may also influence where patients seek scans and which services are ordered. Regulatory clearance confirms a permitted product status for the specified use, not guaranteed adoption or clinical outcomes. Subsequent company disclosures may clarify the number of active customer sites, scan volumes, recurring software Revenue and operating expenditure associated with commercial expansion.

Key Insights

4DMedical (ASX:4DX) has added a nationwide outpatient distribution relationship for two lung-analysis products, CT:VQ and LDAf. The development is identifiable as a commercial-access milestone, with no published financial impact in the November announcement. Its significance can be evaluated alongside FY2026 reporting, future usage disclosures and the practical conditions affecting referrals, reimbursement and integration into existing imaging workflows.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.